Intrinsic Alpha

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

Returns on capital

Hemab Therapeutics Holdings, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

36.2%

avg 36.2%

ROIC

-37.8%

avg -37.8%

ROA

-32.8%

avg -32.8%

Analysis

ROE is currently the strongest return metric at 36.2% versus its period average of 36.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Benny Sorensen

President, CEO & DirectorUSD 819.67K52——

Mads Nikolaj Behrndt-Eriksen

CFO & GMUSD 689.14K43——

Catherine Madigan

Chief Medical OfficerUSD 640.56K54——

Karen Weisbach

Chief People & Culture Officer————

Cecile Bonvoisin

Senior Vice President of CMC & Manufacturing————

Ananthram Sreenivasa Murthy

Chief Operating Officer—48——

Tara O'Meara

Senior Vice President of Development Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Hemab Therapeutics Holdings, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about COAG's management, answered from reported figures.

Who manages COAG?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) lists 7 active executives. The top listed executive is Karen Weisbach, Chief People & Culture Officer.

Are COAG insiders buying or selling?

Recent insider activity shows net buying of $1.29M.